373 Background: Long term adverse symptoms following treatment for prostate cancer are prevalent and can negatively impact quality of life and increase healthcare seeking, even though many symptoms can be effectively self-managed. There remains a need for tools to support long term survivors to feel confident in their ability to self-manage their symptoms, potentially translating to more efficient health care utilization. Methods: We conducted a RCT of an automated tailored self-management support intervention (vs. newsletter) for long term (> 1 year) Veteran survivors of prostate cancer recruited from 4/2015-2/2017 across four VA sites. Participants were randomized (278 per arm) and assessed via survey at 5 months and 12 months post enrollment. The intervention delivered tailored information regarding symptoms for urinary, sexual, bowel and general health over 3 months, allowing participants to choose focus areas. At 12 months, we assessed secondary trial outcomes; participants’ reports of use of services relative to their symptoms (urinary, bowel, sexual, general health) and their confidence in symptom self-management (scale from 5-15). We also assessed use of procedures and medications related to each symptom area via medical charts. We tested differences in reported and documented service use between arms using T-tests and Chi-square tests. We further assessed participants engagement in components of the intervention. Results: Of those randomized, 81.7% completed the 12-month survey assessment (N = 226 Intervention and N = 228 Control). The average age was 66.7, 28% were Black, and 49% were high school graduates or less. Participants in the intervention arm reported greater confidence in symptom self-management than controls (Mean: 13.5 vs. 12.9; P = 0.01). Intervention participants reported less often using services related to urinary (43.9% vs. 56.0%, P = 0.03) and sexual (42.3% vs. 57.6%, P = 0.04) health over the prior 7 months. Review of intervention paradata found that urinary and sexual health were the topics most frequently engaged with among intervention subjects. No significant differences in medical chart documented procedures related to symptom areas were found. Conclusions: This secondary trial analysis found that 12 months post enrollment, Veterans who engaged with a tailored self-management intervention were more confident in their ability to self-manage their symptoms. The associated finding of fewer visits for the most commonly chosen areas for symptom self-management suggests that such an intervention may hold promise for helping long term survivors to effectively self-manage adverse symptoms. Clinical trial information: NCT01900561.

5011 Background: The purpose of this randomized trial was to compare a personally-tailored symptom management intervention consisting of 4 automated telephone assessments and tailored education for improving symptom self-management among prostate cancer survivors to usual care (1 non-tailored newsletter about symptom management). We hypothesized improved symptom self-management and prostate cancer quality of life following the intervention. Methods: A total of 556 prostate cancer survivors experiencing symptom burden were recruited from April 2015 to February 2017 across 4 sites. Participants were randomized to intervention (n = 278) and usual care (n = 278) groups as reported in our protocol. Our primary outcome was symptom burden assessed via patient report 5 months after enrollment using the EPIC-26 instrument. Secondary outcomes included psychosocial outcomes and domain-specific changes according to intervention participants’ primary symptom area (urinary, bowel, sexual, general). We used multivariable regression analysis to evaluate intervention impact on outcomes. Results: The mean age of prostate cancer survivors was 66.7 years and the majority was treated with radiation therapy (56.7% vs. 46.2% surgery). The 5 month primary outcome assessment was completed by 89% of participants. There were no baseline differences across groups. At 5 months, we observed differences between groups in urinary domains (irritative - 61.8 control vs. 63.4 intervention, adjusted mean difference (aMD) 2.6, p = 0.07; obstructive - 74.5 control vs. 77.4 intervention, aMD 2.6, p = 0.07) with no significant differences in other outcomes. Intervention participants choosing urinary (crude mean difference (cMD) irritative 3.0; p = 0.09, obstructive 6.1; p < 0.01), bowel (cMD 9.1; p = 0.08), and sexual (cMD 5.6; p < 0.01) domains as their primary focus area reported improvements at 5 months. Participants reported high satisfaction with the intervention. Conclusions: A personally-tailored, automated telephone symptom management intervention for prostate cancer survivors was feasible and led to differences in urinary and sexual health symptoms in this randomized trial. Self-management of treatment-related side effects appears warranted. Clinical trial information: NCT01900561.